“Rising Adoption of Targeted Biologic Therapies”
- A significant and accelerating trend in the global myasthenia gravis treatment market is the growing preference for biologic and targeted therapies, particularly monoclonal antibodies and complement inhibitors, which offer improved efficacy in managing moderate to severe cases and treatment-resistant patients
- For instance, eculizumab and ravulizumab, both complement C5 inhibitors, have demonstrated sustained reduction in symptom severity and hospitalizations, especially in patients with refractory generalized myasthenia gravis (gMG). Their success has catalyzed further development of precision therapies in the immunoneurology space
- There is also increasing clinical and commercial momentum behind FcRn inhibitors such as efgartigimod and rozanolixizumab, which work by reducing pathogenic IgG antibodies that contribute to neuromuscular junction dysfunction. These agents offer a novel approach for patients unresponsive to standard cholinesterase inhibitors and corticosteroids
- The integration of newer biologics into treatment guidelines is reshaping how neurologists manage the disease, shifting from broad immunosuppressive regimens to more targeted, patient-specific options with favorable safety profiles
- Moreover, the expansion of clinical trials, real-world evidence data, and increasing FDA and EMA approvals for novel treatments are strengthening physician confidence and expanding access to next-generation therapies
- This shift toward personalized immunotherapy is redefining standards of care for Myasthenia Gravis, creating substantial market opportunities for pharmaceutical innovators and driving sustained investment into autoimmune neurology pipelines
